top of page

Diseases

A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Paper Abstract

Phase II, single arm study of NOVOTTF-200A In bevacizumab-naive subjects with recurrent WHO grade III Malignant Astrocytoma

Summary

“This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second-line treatment and who have not previously received any BEV or any experimental agents.”

Description

Primary objective:

The primary objective will be to determine the efficacy of NOVOTTF-200A in recurrent anaplastic astrocytoma patients (6-month progression-free survival)

Secondary objectives:

  • To evaluate the safety of NOVOTTF-200A in the subject population.

  • To evaluate the efficacy of NOVOTTF-200A in the subject population.

  • To see if the presence of ATRX, TERT promoter, IDH1 mutations, and/or MGMT promoter methylation, confers a better response to NOVOTTF-200A.

  • To determine if the treatment significantly modifies the patient’s quality of life. The sponsor will use the Functional Assessment of Cancer Therapy (FACT) questionnaires:
         1. FACT-Brain (FACT-Br)
         2. FACT-Cognitive Function (FACT-Cog)

 

Exploratory objectives:

  • To determine if the presence of pro-neural or mesenchymal phenotype (Cytoscan analysis) confers a better response to Novo-TTF.

  • To determine if the in vitro sensitivity of the glioma cells derived from patient specimens before and after the NOVOTTF-200A treatment correlates with the patient’s response to treatment.

dfd.jpg

Related clinical trials

Phase I/II trial of repeated super-selective intraarterial cerebral infusion of...

The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all...

Phase I-II study evaluating HSV-tK + valacyclovir gene therapy combination...

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy, and chemotherapy in newly...

Collaborators

IIT Guwahati
University of Manchester
Rhenix Lifesciences
American university of Sharjah
IIT Delhi

Get new content delivered directly to your inbox.

bottom of page